Karolinska Development’s portfolio company Aprea Therapeutics appoints a new Chief Medical Officer

STOCKHOLM, March 25, 2019. Karolinska Development’s portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 12

Ähnlich Nachrichten